An observational study in Intracranial Atherosclerosis, Optical Coherence Tomography and Plaque, Atherosclerotic, sponsored by jiaoliqun. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by jiaoliqun · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Intracranial Arteriosclerosis with a site in China — 28 open to participants now, 28 under way, 2 of them phase 3. Intracranial Arteriosclerosis · China.
Among the 44 studies in Intracranial Arteriosclerosis with a site in China, this one is the 6th largest by planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2020, is one of 17 observational ones, reaches primary completion later than 15 of the 27 other live ones, and was the 18th registered.
103 studies on the registry are indexed under Intracranial Arteriosclerosis; 49 are open to participants now.
Browse Intracranial Arteriosclerosis studies →28 of the 44 studies in Intracranial Arteriosclerosis with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
Peking Union Medical College Hospital · Sites in China
Ages 18–80
Xuanwu Hospital, Beijing · Sites in China
Ages 18+ · Healthy volunteers
Qianfoshan Hospital · Sites in China
Ages 18–80
Fujian Medical University Union Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 29 Intracranial Arteriosclerosis studies recruiting now, 12 (41%) set no upper age limit and 1 (3%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3 · Phase 4 8
First in 2007; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 200 across 35 observational studies indexed under Intracranial Arteriosclerosis.
Median enrollment 200 across the 27 interventional studies, 300 across the 17 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 44 have an industry lead sponsor. The 10 most frequent:
jiaoliqun is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
jiaoliqun has 1 study filed under Intracranial Arteriosclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Intracranial Arteriosclerosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06925971Phase 3MicroPort NeuroTech Co., Ltd.A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease(TARGET-DREAM) | 2027-10-01 |
| NCT07445581Jinggang Xia, MDTanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients | 2026-12-31 |
| NCT06881420Fujian Medical University Union HospitalBASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease | 2026-12-31 |
| NCT05550077jiaoliqunOptical Coherence Tomography for Intracranial Atherosclerotic Stenosis | 2026-12-31 |
| NCT07927569Qianfoshan HospitalIntegrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA Occlusion | 2027-01-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 44 studies in Intracranial Arteriosclerosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).
Stroke was the second leading cause of death worldwide and the leading cause of death in China in 2017. ICAS accounted for 10% to 15% of ischemic stroke in Western countries, and as much as 46.6%in Asia in 2009.
For patients with ICAS, the risk of stroke is highly related to the histopathology of atheromatous plaques. Therefore, characterizing the morphology and composition of plaques in ICAS may help to predict the risk of stroke occurrence and allow the adoption of preventive or therapeutic management to prevent such life-threatening events. OCT, with a resolution of 10μm, may provide more reliable information in characterizing atheromatous plagues.
This study aims to get a better insight into the value of OCT in evaluating the vessel wall structure and therefore guiding the interventional therapy of ICAS. In addition, the clinical and biological information will be included to achieve correlation analysis so as to get biomarkers subject to various plaque characteristics.
Adults (aged over 18) with symptomatic ICAS (≥ 50%) will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.
Diagnostic Test: Optical Coherence Tomography · Procedure: Percutaneous transluminal angioplasty and stenting
Classical imaging evaluation such as TCCD and High resolution-MRI will be performed, followed by standard percutaneous transluminal angioplasty and stenting.
Procedure: Percutaneous transluminal angioplasty and stenting
Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
Safety outcomes: short-term death or stroke
We defined 'short-term' as the periprocedural period, or mean follow-up time less than or equal to three months after enrollment. Stroke was identified in the vascular territory of the stenosed vessel, either ischaemic or haemorrhagic. We defined death or stroke as a composite of death of any cause or non-fatal stroke of any type in any territory.
Time frame: 30 days after enrollment
Death or stroke
(long term; more than three months)
Time frame: 1 year after enrollment
Ipsilateral stroke
(same territory as the index stenosis)
Time frame: 1 year after enrollment
Type of recurrent event
(TIA, ischaemic stroke, haemorrhagic stroke)
Time frame: 1 year after enrollment
Death
(long term; more than three months)
Time frame: 1 year after enrollment
Restenosis
(≥ 50%) of the involved vessel documented by conventional cerebral angiography
Time frame: 1 year after enrollment
Dependency
Modified Rankin Scale or equivalent
Time frame: 1 year after enrollment
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2020 (actual). Primary completion is estimated for Dec 2026, 81 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intracranial Arteriosclerosis →
jiaoliqun